Glutamate (Metabotropic) Group I Receptor Modulators
| Cat. No. | 产品名称/活性 |
|---|---|
| 4416 | ADX 10059 hydrochloride |
| Negative allosteric modulator of mGlu5 receptors | |
| 3235 | CDPPB |
| Positive allosteric modulator of mGlu5 receptors | |
| 2386 | Fenobam |
| Potent and selective mGlu5 negative allosteric modulator (NAM) | |
| 6859 | FITM |
| Potent and selective negative allosteric modulator of mGlu1 receptors | |
| 5000 | FTIDC |
| Potent and selective negative allosteric modulator of mGlu1 receptors; also mGlu1 inverse agonist | |
| 5275 | LSN 2463359 |
| Potent and selective positive allosteric modulator of mGlu5 receptors | |
| 4347 | Ro 67-4853 |
| Positive allosteric modulator of group I mGlu receptors | |
| 4346 | Ro 67-7476 |
| Positive allosteric modulator of mGlu1 receptors | |
| 4323 | VU 0360172 hydrochloride |
| Positive allosteric modulator of mGlu5 receptors | |
| 5693 | VU 0409551 |
| Selective positive allosteric modulator of mGlu5 receptors; brain penetrant and orally bioavailable | |
| 5379 | VU 0469650 hydrochloride |
| Potent and selective negative allosteric modulator of mGlu1 receptors |
mGlu Receptors Scientific Review
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyRequest PDFAddiction Life Science Poster
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFDepression Life Science Poster
Written by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFHuntington's Disease Life Science Poster
Our Huntington's Disease (HD) poster summarizes the pathophysiology and molecular changes that occur in HD.
Request copyDownload PDFParkinson's Life Science Poster
Written by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF